지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2024.3
- 수록면
- 28 - 34 (7page)
- DOI
- 10.5392/IJoC.2024.20.1.028
이용수
초록· 키워드
오류제보하기
Gut microbiota, regarded as the second genome of the human body, has become a key modulator of cancer treatment. It is an emerging topic in precision medicine, and many studies have reported that the variability in most diseases and individuals is related to gut microbiota characteristics. Numerous clinical studies on cancer treatment have demonstrated a correlation between therapeutic responses to immunotherapeutic cancer drugs and gut immunity or the microbiome. In this paper, we present the current clinical research on herbal medicines and gut microbiota and explore the possibility of integrative cancer treatment with herbal medicines and immunotherapeutic cancer drugs. We identified six clinical trials enrolled in the Clinical Research Information Service and five clinical studies on gut microbiota and herbal medicines in MEDLINE via PubMed. Generally, clinical studies have used 16S rRNA sequencing to analyze the gut microbiota. Study findings have suggested that the gut microbiota can be used as a biomarker to predict the pharmacological effects of herbal medicines. Gut microbiota modifications by herbal medicines may inhibit tumor progression. Herbal medicines are metabolized to active substances through interactions with the microbiome and control the dysbiosis of the gut microbiome. Further research on the possibility of individualized precision medicine by analyzing the gut microbiota after administering herbal medicine is needed.
목차
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
References
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Current understanding of the Alzheimer’s disease-associated microbiome and therapeutic strategies
Experimental and Molecular Medicine
2024 .01
-
Bioactive Microbiota Metabolites in The Mouse Gut
한국생물공학회 학술대회
2017 .04
-
The gut microbiota: a key regulator of metabolic diseases
BMB Reports
2016 .01
-
The interplay between host immune cells and gut microbiota in chronic inflammatory diseases
Experimental and Molecular Medicine
2017 .01
-
Gut microbiota restoration through fecal microbiota transplantation: a new atopic dermatitis therapy
Experimental and Molecular Medicine
2021 .05
-
Role of the gut–brain axis in energy and glucose metabolism
Experimental and Molecular Medicine
2022 .04
-
Poly-(γ-D-Glutamic Acid) Ameliorates Metabolic Dysfunction by Modulating Metabolic Gene Expression and Attenuating Intestinal Barrier Injury
한국생물공학회 학술대회
2022 .09
-
Disruption of the Gut Microbiome in Protein Losing Enteropathy Dogs
한국생물공학회 학술대회
2022 .04
-
Gut microbiota-generated metabolites: missing puzzles to hosts’ health, diseases, and aging
BMB Reports
2024 .05
-
Dysregulation of gut microbiota and chronic inflammatory disease: from epithelial defense to host immunity
Experimental and Molecular Medicine
2017 .01
-
발모 향상을 위한 한약재의 개발 및 효과 확인
KSBB Journal
2016 .12
-
Exercise training modulates the gut microbiota profile and impairs inflammatory signaling pathways in obese children
Experimental and Molecular Medicine
2020 .01
-
Roles of intestinal epithelial cells in the maintenance of gut homeostasis
Experimental and Molecular Medicine
2017 .01
-
Engineering Strategies to Modulate the Gut Microbiome and Immune System
한국고분자학회 학술대회 연구논문 초록집
2022 .04
-
Multiomics Approach for Targeting Novel Microbiome Therapeutics against Chronic Diseases
한국생물공학회 학술대회
2021 .04
-
Influence of prebiotic carbohydrate on the gut microbiome
한국생물공학회 학술대회
2018 .10
-
Engineering Genetic Circuits for Sensing Gut Inflammation
한국생물공학회 학술대회
2021 .04
-
A Novel In Vitro Human Colon Model System for Investigating Interaction of Gut Microbes with Human Cells
한국생물공학회 학술대회
2021 .10
-
Development of a Multi-Organ Chip for Investigating Gut-Skin Axis
한국생물공학회 학술대회
2023 .10
-
Slimy partners: the mucus barrier and gut microbiome in ulcerative colitis
Experimental and Molecular Medicine
2021 .05
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-151-24-02-090398382